

## Special Issue

# Bioengineering in Vaccine Design and Delivery

### Message from the Guest Editor

During vaccine development, it is essential to improve delivery and manufacturing methods to reach the safe, effective, and cost-effective vaccine production criteria. Advances in bioengineering have made it possible to control the physicochemical properties of the vaccines for faster synthesis, improve the antigen presentation to get more robust immunogenicity of vaccines, and obtain safer vaccine formulas. Recent developments in vaccine delivery include the development of various polymeric particles as vaccine carriers due to their high biocompatibility and biodegradability. It is also shown that biodegradable hyaluronic cryogel mediates sustained antigen and adjuvant release, leading to a durable immune response. Proof of concept studies in vitro and in vivo will also be considered. Virus-like particles as vaccine carriers efficiently elicit the immune response and offer improved safety, especially for immunocompromised or elderly patients. Scientists working on different strategies to improve vaccine effectiveness, safety, or manufacturing using bioengineering technology are welcome to submit their work to this Special Issue by August 2024.

### Guest Editor

Prof. Dr. Massimo Zollo

Department of Molecular Medicine and Medical Biotechnology,  
Federico II Faculty of Naples, 80138 Napoli, Italy

### Deadline for manuscript submissions

1 November 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/189745](https://mdpi.com/si/189745)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).